Tayna Felicissimo Gomes de Souza Bandeira

Tayna Felicissimo Gomes de Souza Bandeira

Auto-generated profile, based on publicly available information

Tayna Felicissimo Gomes de Souza Bandeira

Faculty of Pharmacy Fluminense Federal University Niteroi RJ Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2022 in Arquivos Catarinenses de Medicina
Verified
Journal Article
Open access
PDF file
GMGabriela Mosegui
Gabriela Mosegui
TBTayna Felicissimo Gomes de Souza Bandeira
Tayna Felicissimo Gomes de Souza Bandeira
CVCid Manso de Mello Vianna
Cid Manso de Mello Vianna
AGAlfonso J. Gil
Alfonso J. Gil
As doenças cardiovasculares (DCV) são um importante problema de saúde pública. Sua carga não foi avaliada de forma abrangente na América do Sul (AS). Este estudo descreveu a carga de DCV na região, em 2019.Trata-se de um estudo exploratório de base populacional, entre os 12 países do subcontinente, de abordagem quantitativa para incidência, mortalidade e anos de vida ajustados por incapacidade (AVAI) por faixa etária padronizada. Capturou-se as medidas a partir do Burden Study Global Disease, Injury and Risk Factors (GBD) 2019, no sítio eletrônico do Institute for Health Metrics and Evaluation (IHME). Análises de correlação foram realizadas entre variáveis sócioeconômicas, demográficas e sanitárias. A taxa de incidência padronizada por idade por 100.000 pessoas para DCV é mais baixa na Bolívia (295) e mais alta no Uruguai (840). As taxas de mortalidade padronizadas foram menores no Peru (86) e mais altas na Guiana (315). A Guiana apresentou a maior taxa padronizada de AVAI (7.792), enquanto o Peru apresentou a menor (1.755). Os anos de vida perdidos (AVP) são o componente mais importante dos AVAI, sendo mais expressivos na Guiana e Suriname (7.528 e 5.304, respectivamente). Existe correlação entre algumas variáveis econômicas e a carga da doença. O presente estudo fornece estimativas abrangentes da carga de DCV para a região. Chama a atenção a grande incidência e considerável mortalidade e AVAI, levando a reflexões sobre medidas de promoção, prevenção e tratamento, além de investigações epidemiológicas mais profundas.

20 October 2025 in DESAFIOS - Revista Interdisciplinar da Universidade Federal do Tocantins
Verified
Journal Article
Open access
PDF file
CVCid Manso de Mello Vianna
Cid Manso de Mello Vianna
GMGabriela Mosegui
Gabriela Mosegui
TLTácio de Mendonça Lima
Tácio de Mendonça Lima
TBTayna Felicissimo Gomes de Souza Bandeira
Tayna Felicissimo Gomes de Souza Bandeira
A osteoporose é uma doença caracterizada por baixa massa óssea e deterioração da qualidade óssea, resultando em aumento do risco de fratura. Afeta 10 milhões de brasileiros, predominantemente mulheres na pós-menopausa. O objetivo deste estudo é avaliar o impacto econômico do romosozumabe versus teriparatida em mulheres na pós-menopausa com osteoporose grave e falha terapêutica, na perspectiva do Sistema Único de Saúde (SUS). Foi realizada uma análise de custo-minimização (ACM) entre o romosozumabe 210 mg e teripartatida 250 mg x 2,4 ml. O modelo utilizou apenas os custos relacionados com o medicamento para o ciclo completo do uso de ambos. A ACM demonstrou a superioridade do romosozumabe em relação à teriparatida. O custo total do tratamento por paciente produziu uma redução de gastos de 13 mil reais/ano, de acordo com o preço atual de compra da teriparatida. Em todos os cenários, o romosozumabe mostrou-se custo-efetivo quando comparado à teriparatida. O resultado do impacto orçamentário indica a possibilidade de redução nos valores gastos com aquisição de medicamentos. A preços atuais, o uso do romosozumabe tem potencial para economizar recursos de 143 milhões de reais em cinco anos. Em todos os cenários analisados, o uso do romosozumabe produz economia de recursos em comparação à teriparatida.

17 April 2026 in International Journal of Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
TBTayna Felicissimo Gomes de Souza Bandeira
Tayna Felicissimo Gomes de Souza Bandeira
PAPatricia Melo Aguiar
Patricia Melo Aguiar
CVCid Manso de Mello Vianna
Cid Manso de Mello Vianna
GMGabriela Mosegui
Gabriela Mosegui
TLTácio de Mendonça Lima
Tácio de Mendonça Lima
Aim: To summarize the evidence of efficacy and safety of romosozumab compared to teriparatide for postmenopausal osteoporosis. Methods: A literature search was performed in Medline, the Cochrane Library, CRD, and LILACS until November 2023. We included systematic reviews with meta‐analyses on the use of romosozumab compared to teriparatide in women with postmenopausal osteoporosis. Two authors performed study selection, data extraction, and quality assessment using AMSTAR‐2 and GRADE tools. Results: A total of 725 records were identified, and 13 studies fully met the eligibility criteria. Regarding efficacy, romosozumab did not show a significant difference in risk of falls (12/24 months), vertebral fractures (12/36 months), non‐vertebral fractures (12/36 months), and hip fractures compared to teriparatide. For the safety profile, romosozumab did not show significant change compared to teriparatide for serious adverse events (12/26 months) and composite cardiovascular outcomes (3PMACE and 4PMACE). The overall quality of evidence in the reviews ranged from very low to moderate, primarily due to indirectness and imprecision in the outcomes. Additionally, the reviews were classified as having “low” or “critically low” methodological quality. Conclusion: Romosozumab demonstrated efficacy and safety similar to teriparatide. However, this overview revealed substantial overlap among primary studies, with most outcomes assessed through indirect comparisons and poor methodological quality. Future research should confirm these findings.

2 January 2026 in JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA
Verified
Journal Article
Open access
PDF file
TLTácio de Mendonça Lima
Tácio de Mendonça Lima
TBTayna Felicissimo Gomes de Souza Bandeira
Tayna Felicissimo Gomes de Souza Bandeira
CVCid Manso de Mello Vianna
Cid Manso de Mello Vianna
GMGabriela Mosegui
Gabriela Mosegui
Esta revisão teve como objetivo sintetizar evidências sobre a eficácia e segurança do fingolimode no tratamento da Esclerose Múltipla Remitente Recorrente (EMRR). Foi realizada busca nas bases Medline, Biblioteca Cochrane, EMBASE e LILACS até fevereiro de 2025. Incluíram-se revisões sistemáticas com meta-análises que compararam o fingolimode a outros tratamentos em adultos com EMRR de baixa ou moderada atividade. A seleção dos estudos, extração dos dados e avaliação da qualidade metodológica foram feitas por dois autores independentes, com uso das ferramentas AMSTAR-2 e GRADE. Três estudos foram incluídos. Em termos de eficácia, duas revisões mostraram que o fingolimode reduziu significativamente a taxa anual de surtos (26% a 48%), e uma apontou redução de cerca de 35% de surtos em 24 meses. Quanto à progressão da incapacidade em 24 meses, não houve diferença relevante entre o fingolimode e os comparadores. Em relação à segurança, uma revisão indicou que os eventos adversos graves foram semelhantes entre o fingolimode e a maioria dos comparadores, com exceção do interferon β-1a. A qualidade metodológica das revisões variou de "criticamente baixa" a "alta", e a qualidade das evidências, de "muito baixa" a "moderada". O fingolimode mostrou superioridade em relação ao acetato de glatirâmer, interferons β-1a e β-1b e à teriflunomida na redução da taxa de surtos, mas não na progressão da incapacidade. Apesar dos resultados favoráveis, estes devem ser interpretados com cautela, pois os dados de eficácia provêm de ensaios clínicos de curto prazo, sem refletir a efetividade ao longo do curso da EMRR.

2 October 2024 in JMIR Preprints
Verified
Preprint
Open access
AMAna Cláudia Medeiros-De-Souza
Ana Cláudia Medeiros-De-Souza
LLLuana Emanuelly Sinhori Lopes
Luana Emanuelly Sinhori Lopes
TBTayna Felicissimo Gomes de Souza Bandeira
Tayna Felicissimo Gomes de Souza Bandeira
LCLucas Reis Correia
Lucas Reis Correia
NSNaiza Sa
Naiza Sa
BOBruno Zocca de Oliveira
Bruno Zocca de Oliveira
BACKGROUND Initiated in 2021, a Brazilian project has the objective of establishing a national injury registry that compiles comprehensive data on events and individuals nationwide, regardless of injury severity. The registry integrates information from pre-hospital and hospital care, various health systems lacking interoperability, and data from sectors such as firefighters and police. Its primary aim is to enhance health surveillance by providing timely, high-quality information that guides prevention strategies and informs policymaking. Additionally, the project seeks to reduce morbidity and mortality associated with injuries. OBJECTIVE This study investigates the effects of injury registry data on policymaking, hospitalization rates or duration, and mortality. METHODS The systematic review followed PRISMA guidelines, with a protocol registered in PROSPERO. Five databases were searched in November 2023, with an update conducted in March 2024, incorporating reference lists from the studies included. Two reviewers independently screened records, extracted data, and assessed methodological quality using the Newcastle-Ottawa Scale (NOS), resolving disagreements with a third reviewer. Studies were eligible if they reported results related to the implementation and use of injury or trauma registry data for at least one outcome of interest, while those based on other sources were excluded. Synthesis of results was presented in tables, and the observed effects were reported as number or percentage differences. RESULTS Out of 9,100 studies retrieved, 3,951 were excluded due to duplication, leaving 5,149 for selection, with 15 full texts reviewed. Only five studies met the inclusion criteria, highlighting a notable scarcity of research on the effects of registry data on injury outcomes. It's important to note that the studies included reflect correlations rather than causalities, and there are currently no publications on impact. The findings suggest that injury and trauma registries positively influence policymaking, which, in turn, enhances health outcomes. One study noted a 3-day reduction in intensive care unit stay and a 4.1% reduction in expected hospital mortality (from 22.8% to 18.7%) for patients with an Injury Severity Score (ISS) ≥ 16, while another showed a 42% annual decrease in traffic injury hospital admissions (from 45 to 16). Significant methodological heterogeneity and the small number of studies limited the feasibility of a meta-analysis. CONCLUSIONS Establishing an injury registry in Brazil presents a significant opportunity to enhance health outcomes through informed policymaking. While the direct effects on morbidity and mortality may not be immediately evident, the registry's role in facilitating preventive measures and improving surveillance capabilities is invaluable.

10 September 2025 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
AMAna Cláudia Medeiros-De-Souza
Ana Cláudia Medeiros-De-Souza
LLLuana Emanuelly Sinhori Lopes
Luana Emanuelly Sinhori Lopes
TBTayna Felicissimo Gomes de Souza Bandeira
Tayna Felicissimo Gomes de Souza Bandeira
LCLucas Reis Correia
Lucas Reis Correia
NSNaiza Sa
Naiza Sa
BOBruno Zocca de Oliveira
Bruno Zocca de Oliveira
Background: The Brazilian project, launched in 2021, aims to establish a nationwide injury registry that systematically collects detailed information on incidents and individuals across the country, regardless of injury severity. The registry integrates information from prehospital and hospital care, various health systems lacking interoperability, and data from sectors such as firefighters and police. Its primary aim is to enhance health surveillance by providing timely, high-quality information that guides prevention strategies and informs policymaking. In addition, the project seeks to reduce morbidity and mortality associated with injuries. Objective: This study aimed to investigate the effects of injury registry data on policymaking, hospitalization rates or duration, and mortality. Methods: The systematic review followed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, with a protocol registered in PROSPERO (International Prospective Register of Systematic Reviews, CRD42023481528). A total of 5 databases were searched in November 2023, with an update conducted in March 2024, incorporating reference lists from the studies included. Two reviewers independently screened records, extracted data, and assessed methodological quality using the Newcastle-Ottawa Scale, resolving disagreements with a third reviewer. Studies were eligible if they reported results related to the implementation and use of injury or trauma registry data for at least one outcome of interest, while those based on other sources were excluded. Synthesis of findings was presented in tables, and the observed results were reported as number or percentage differences. Results: Out of 9100 studies retrieved, 3951 were excluded due to duplication, leaving 5149 for selection, with 15 full texts reviewed. Only 5 studies met the inclusion criteria, highlighting a notable scarcity of research on the effects or results of registry data on injury outcomes. It is important to note that the studies included reflect correlations rather than causalities, and there are currently no publications on impact. The findings suggest that injury and trauma registries have the potential to inform policymaking, which can lead to enhanced health outcomes. One study noted a 3-day reduction in intensive care unit stay (from 16 to 13 days; P<.05) and a 4% reduction in expected hospital mortality (from 17.5% to 21.5%) for patients with an Injury Severity Score ≥16, while another showed a 42% annual decrease in traffic injury hospital admissions (from 45 to 16). Significant methodological heterogeneity and the small number of studies limited the feasibility of a meta-analysis. Conclusions: Establishing an injury registry in Brazil presents a significant opportunity to enhance health outcomes through informed policymaking. While it is crucial to set appropriate expectations regarding its effects on morbidity and mortality, particularly concerning the causality and transportability of the findings to the Brazilian context, its role in facilitating preventive measures and improving surveillance capabilities remains valuable.